Evidence map›Paper›PMID 33563539›Full record

ArticleUrologic oncology2021

Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.

Gang Wang, Peter C Black, Peter J Goebell, Lingyun Ji, Carlos Cordon-Cardo, Bernd Schmitz-Dräger, Debra Hawes, Bogdan Czerniak, Sarah Minner, Guido Sauter and 4 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 3 countries.

Gang WangDepartment of Pathology, University of British Columbia, Vancouver, Canada.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: pblack@mail.ubc.ca.
Peter J GoebellDepartment of Urology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.
Lingyun JiDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Carlos Cordon-CardoDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York City, NY.
Bernd Schmitz-DrägerDepartment of Urology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany; Urologie 24, Nürnberg, Germany.
Debra HawesDepartment of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Bogdan CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sarah MinnerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frederic WaldmanDepartment of Laboratory Medicine and Urology, University of California San Francisco, San Francisco, CA.
Susan GroshenDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Richard J CoteDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
Colin P DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
University of Southern California · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CAIcahn School of Medicine at Mount Sinai · USUniversität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of California, San Francisco · USWashington University in St. Louis · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
MVAC IN ORGAN-CONFINED BLADDER CANCER BASED P53 STATUSR01CA071921 · NCI · YALE UNIVERSITY · PI COTE, RICHARD JAMES · 1997 to 2006
$3.0M
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancerU01CA233363 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI AGARWAL, ASHUTOSH, COTE, RICHARD JAMES · 2018 to 2022
$2.6M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NCI NIH HHS R01 CA071921NCI NIH HHS U01 CA233363
6 · The paper itself

Abstract

purposeWe evaluated the prognostic value of 10 putative tumor markers by immunohistochemistry in a large multi-institutional cohort of patients with locally advanced urothelial cancer of the bladder (UCB) with the aim to validate their clinical value and to harmonize protocols for their evaluation. MATERIALS AND

methodsPrimary tumor specimens from 576 patients with pathologic (p)T3 UCB were collected from 24 institutions in North America and Europe. Three replicate 0.6-mm core diameter samples were collected for the construction of a tissue microarray (TMA). Immunohistochemistry (IHC) for 10 previously described tumor markers was performed and scored at 3 laboratories independently according to a standardized protocol. Associations between marker positivity and freedom from recurrence (FFR) or overall survival (OS) were analyzed separately for each individual laboratory using Cox regression analysis.

resultsThe overall agreement of the IHC scoring among laboratories was poor. Correlation among the 3 laboratories varied across the 10 markers. There was generally a lack of association between the individual markers and FFR or OS. The number of altered cell cycle regulators (p53, Rb, and p21) was associated with increased risk of cancer recurrence (P < 0.032). There was no clear pattern in the relationship between the percentage of markers altered in an 8-marker panel and FFR or OS.

conclusionsThis large international TMA of locally advanced (pT3) UCB suggests that altered expression of p53, Rb, and p21 is associated with worse outcome. However this study also highlights limitations in the reproducibility of IHC even in the most expert hands.

Indexed as

AgedBiomarkers, TumorCarcinoma, Transitional CellCohort StudiesFemaleHumansImmunohistochemistryInternational CooperationMaleMicroarray AnalysisMiddle AgedNeoplasm StagingPrognosisSurvival RateUrinary Bladder NeoplasmsBiomarkers, TumorBladder cancerPrognostic MarkersTissue microarray

Identifiers

PMID33563539
PMCPMC8501538
OpenAlexW3127046624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.